Efficacité et tolérance du dichlorure de radium 223 chez les patients traités pour cancer de la prostate résistant à la castration avec métastases osseuses

Introduction

The aim of our study was to evaluate the efficacy and tolerance of ²²³RaCl₂ in patients with mCRPC with bone metastases, then analyse the impact of any change in treatment protocol on the efficacy of ²²³RaCl₂ in mCRPC patients with bone metastases, by determining overall survival, progression-free survival and events occurring during therapeutic monitoring.

Materiel and methods

Our retrospective, analytical and descriptive study, carried out in Luxembourg, included patients eligible for le ²²³RaCl₂ treatment who were assessed during and at the end of treatment, and 3 to 4 months after the end of treatment.

Results

Our sample included 41 cases. The mean age of patients was 74 years (min = 52, max = 87), with 32 (78.1%) deaths recorded. Median overall survival was 18.0 months (95% CI: 12.1–23.9): 11 months for those who experienced progression during treatment versus 47 months for those who experienced a partial response. Median progression-free survival was 15.0 months (95% CI: 0.0–36.4). Overall survival was positively correlated with progression-free survival (Rho Spearman = 0.713, P-value < 0.001); however, a one-month increase in progression-free survival decreased the risk of death by 6% and thus increased overall survival (HR = 0.937, 95% CI : 0.903–0.973, P < 0.001).

Conclusion

Administration of the complete ²²³RaCl₂ protocol improved overall survival and progression-free survival in patients treated for mCRPC with bone metastases, with good hematological tolerability despite the occurrence of complications such as epiduritis and fractures.